Compounded semaglutide dosing errors; type 1 diabetes immunotherapy

0
Compounded semaglutide dosing errors; type 1 diabetes immunotherapy

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].

The FDA has received reports of adverse events, including gastrointestinal events, fainting, headache, migraine, dehydration, acute pancreatitis and gallstones, that may be tied to overdosing with compounded semaglutide.

The overdosing may be due to a lack of experience with self-injections among patients and errors with converting measurement units, according to the agency.



FDA headquarters

The FDA has received reports of adverse events associated with compounded injectable semaglutide. Errors in dosing and a lack of dosing experience may be to blame, the agency said. Image: Adobe Stock

Patients, providers and compounders have been advised to speak with each other about measuring and administering the proper dose of compounded semaglutide.

It was the top story in endocrinology last week.

In another top story, the FDA granted a second fast-track designation for an immunotherapy to treat pediatric patients with early-stage type 1 diabetes who have the DR3-DQ2 genotype.

“This recognition once again underscores the potential of our precision medicine approach and the urgent need for new treatment options for type 1 diabetes across the disease spectrum,” Ulf Hannelius, CEO of Diamyd Medical, said in a company press release.

Read these and more top stories in endocrinology below:

FDA warns of adverse events due to overdosing of compounded semaglutide

The FDA is warning providers and patients that dosing errors with compounded injectable semaglutide may be leading to adverse events, according to a press release. Read more.

Immunotherapy to treat early-stage type 1 diabetes receives FDA fast track designation

An immunotherapy to treat type 1 diabetes for people with the human leukocyte antigen DR3-DQ2 genotype received its second fast-track designation from the FDA, according to a company press release. Read more.

Semaglutide does not raise risk for neurologic disorders for adults with type 2 diabetes

Semaglutide was not associated with increased risks for adverse neurologic or psychological disorders at 1 year compared with other diabetes drugs, according to data published in eClinicalMedicine. Read more.

Voluntary medical device correction issued for small subset of FreeStyle Libre 3 sensors

A voluntary medical device correction has been issued for a small number of continuous glucose monitoring sensors distributed in the first half of May, according to an industry press release. Read more.

Postprandial insulin may cut hypoglycemia rates for hospitalized adults with diabetes

Changing in-hospital nutritional insulin administration from before meals to after meals lowered hypoglycemia rates at a community hospital, according to study findings published in Diabetes Research and Clinical Practice. Read more.

link

Leave a Reply

Your email address will not be published. Required fields are marked *